Tourmaline Bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights
Provided By GlobeNewswire
Last update: Aug 13, 2025
– Reported positive topline results from the ongoing Phase 2 TRANQUILITY trial of pacibekitug in May 2025, demonstrating rapid, deep, and durable reductions in high-sensitivity C-reactive protein with quarterly dosing –
Read more at globenewswire.comNASDAQ:TRML (9/23/2025, 1:47:57 PM)
47.735
-0.02 (-0.03%)
Find more stocks in the Stock Screener
TRML Latest News and Analysis
